Details of the Drug Reposition

General Information of This Drug (ID: DMB08GE)

• Drug Name: Sulfamethoxazole (DMB08GE)
• Synonyms: sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole
• Therapeutic Class: Antiinfective Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

6 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Inclusion conjunctivitis	DIS55P6V	N.A.	Approved	[1]
Bacterial infection	DIS5QJ9S	1A00-1C4Z	Approved	[2]
Bacillary dysentery	DISFZHKN	1A02	Approved	[1]
Tuberculosis	DIS2YIMD	1B10-1B14	Approved	[1]
Acute otitis media	DISL8D8G	AB00	Approved	[1]
Pneumocystis pneumonia	DISFSOM3	CA40.20	Approved	[1]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Toxoplasmosis	DISYP8FH	1F57	Withdrawn	[3]

2 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Nocardiosis	DISQ8HYY	N.A.	Discontinued in Phase 2	[4]
Bacterial urinary tract infection	DISNNJTF	N.A.	Discontinued in Phase 2	[5]

1 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
HIV infectious disease	DISO97HC	N.A.	Discontinued in Phase 1	[6]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Infection of P. falciparum	DISN7KUQ	1F40	Investigative	[7]

References

• [1] Sulfamethoxazole FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
• [4] Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
• [5] ClinicalTrials.gov (NCT01368263) Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
• [6] Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel
• [7] Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.